Compare ZVIA & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZVIA | VTVT |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.3M | 148.7M |
| IPO Year | 2021 | 2015 |
| Metric | ZVIA | VTVT |
|---|---|---|
| Price | $1.36 | $29.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $4.93 | ★ $53.00 |
| AVG Volume (30 Days) | ★ 385.3K | 103.6K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $161,259,000.00 | N/A |
| Revenue This Year | $8.30 | N/A |
| Revenue Next Year | $6.87 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.01 | N/A |
| 52 Week Low | $1.11 | $14.55 |
| 52 Week High | $3.22 | $44.00 |
| Indicator | ZVIA | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 35.98 | 36.48 |
| Support Level | $1.27 | $22.92 |
| Resistance Level | $1.53 | $33.76 |
| Average True Range (ATR) | 0.11 | 2.07 |
| MACD | -0.04 | -0.22 |
| Stochastic Oscillator | 10.65 | 2.96 |
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.